Compass Therapeutics (NASDAQ:CMPX) Rating Lowered to “Hold” at Leerink Partnrs

Leerink Partnrs downgraded shares of Compass Therapeutics (NASDAQ:CMPX) from a strong-buy rating to a hold rating in a research report released on Friday,Zacks.com reports.

A number of other equities research analysts have also recently issued reports on the company. Leerink Partners downgraded Compass Therapeutics from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $5.00 to $4.00 in a research report on Friday. LADENBURG THALM/SH SH upgraded Compass Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 price objective on the stock in a research note on Monday, September 16th. HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of Compass Therapeutics in a research report on Monday, November 11th. Finally, Wedbush restated an “outperform” rating and issued a $8.00 target price on shares of Compass Therapeutics in a research note on Wednesday, August 7th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $6.75.

Compass Therapeutics Trading Down 2.2 %

Shares of NASDAQ CMPX opened at $1.35 on Friday. The company has a market cap of $185.75 million, a PE ratio of -3.65 and a beta of 0.92. The stock has a 50 day simple moving average of $1.75 and a 200-day simple moving average of $1.41. Compass Therapeutics has a 12-month low of $0.77 and a 12-month high of $2.34.

Compass Therapeutics (NASDAQ:CMPX) last announced its earnings results on Tuesday, November 12th. The company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.03. Sell-side analysts forecast that Compass Therapeutics will post -0.37 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Compass Therapeutics

Large investors have recently modified their holdings of the business. Opaleye Management Inc. acquired a new position in shares of Compass Therapeutics in the first quarter valued at approximately $6,277,000. CM Management LLC grew its holdings in shares of Compass Therapeutics by 148.0% during the first quarter. CM Management LLC now owns 310,000 shares of the company’s stock worth $614,000 after purchasing an additional 185,000 shares during the last quarter. Ground Swell Capital LLC bought a new stake in Compass Therapeutics in the second quarter worth approximately $124,000. Barclays PLC lifted its position in shares of Compass Therapeutics by 195.4% during the 3rd quarter. Barclays PLC now owns 170,245 shares of the company’s stock valued at $314,000 after acquiring an additional 112,614 shares during the period. Finally, Vanguard Group Inc. raised its stake in Compass Therapeutics by 1.7% during the 1st quarter. Vanguard Group Inc. now owns 4,152,197 shares of the company’s stock worth $8,221,000 after buying an additional 71,008 shares during the period. 68.43% of the stock is currently owned by institutional investors and hedge funds.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.